AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia

Journal of Molecular Signaling

Volumn 5, Issue , 2010, Pages

  Leclerc, Gilles M ^a   Leclerc, Guy J ^a   Fu, Guilian ^a   Barredo, Julio C ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956875005     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-5-15     Document Type: Article

References (63)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006, 354:166-178. 10.1056/NEJMra052603, 16407512.
2. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143. 10.1016/S1535-6108(02)00032-6, 12086872.
3. Sengupta TK, Leclerc GM, Hsieh Kinser TT, Leclerc GJ, Singh I, Barredo JC. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol Cancer 2007, 6:46. 10.1186/1476-4598-6-46, 1948012, 17623090.
4. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241. 10.1016/S0092-8674(00)80405-5, 9346240.
5. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997, 278:687-689. 10.1126/science.278.5338.687, 9381178.
6. Virdee K, Parone PA, Tolkovsky AM. Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol 2000, 10:1151-1154. 10.1016/S0960-9822(00)00702-8, 10996800.
7. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101. 10.1126/science.1106148, 15718470.
8. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 1996, 15:6541-6551. 452479, 8978681.
9. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007, 12:487-502. 10.1016/j.devcel.2007.03.020, 17419990.
10. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005, 280:40406-40416. 10.1074/jbc.M508361200, 16221682.
11. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 2005, 15:1839-1846. 10.1016/j.cub.2005.08.066, 16243031.
12. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009, 8:742-753. 10.1158/1535-7163.MCT-08-0668, 19372546.
13. Sale EM, Sale GJ. Protein kinase B: signalling roles and therapeutic targeting. Cell Mol Life Sci 2008, 65:113-127. 10.1007/s00018-007-7274-9, 17952368.
14. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928. 10.1038/sj.leu.2404245, 16642045.
15. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005, 4:1533-1540. 10.1158/1535-7163.MCT-05-0068, 16227402.
16. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004, 14:1650-1656. 10.1016/j.cub.2004.08.026, 15380067.
17. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000, 275:9047-9054. 10.1074/jbc.275.12.9047, 10722755.
18. Schmitz-Peiffer C, Whitehead JP. IRS-1 regulation in health and disease. IUBMB Life 2003, 55:367-374. 10.1080/1521654031000138569, 14584587.
19. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940. 10.1038/sj.onc.1209990, 17001314.
20. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003, 107:873-877. 10.1002/ijc.11487, 14601044.
21. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002, 1:769-783. 10.1038/nrd917, 12360255.
22. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995, 16:3-34.
23. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001, 22:818-835. 10.1210/er.22.6.818, 11739335.
24. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008, 13:16-24. 10.1634/theoncologist.2007-0199, 18245009.
25. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353. 10.1016/S0140-6736(04)16044-3, 15110491.
26. Ross JA, Perentesis JP, Robison LL, Davies SM. Big babies and infant leukemia: a role for insulin-like growth factor-1?. Cancer Causes Control 1996, 7:553-559. 10.1007/BF00051889, 8877054.
27. Merchav S. The haematopoietic effects of growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab 1998, 11:677-685.
28. Vorwerk P, Wex H, Hohmann B, Mohnike K, Schmidt U, Mittler U. Expression of components of the IGF signalling system in childhood acute lymphoblastic leukaemia. Mol Pathol 2002, 55:40-45. 10.1136/mp.55.1.40, 1187145, 11836446.
29. Wex H, Ahrens D, Hohmann B, Redlich A, Mittler U, Vorwerk P. Insulin-like growth factor-binding protein 4 in children with acute lymphoblastic leukemia. Int J Hematol 2005, 82:137-142. 10.1532/IJH97.E0429, 16146846.
30. Mohnike KL, Kluba U, Mittler U, Aumann V, Vorwerk P, Blum WF. Serum levels of insulin-like growth factor-I, -II and insulin-like growth factor binding proteins -2 and -3 in children with acute lymphoblastic leukaemia. Eur J Pediatr 1996, 155:81-86. 10.1007/BF02075755, 8775218.
31. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem 2001, 276:46912-46916. 10.1074/jbc.C100483200, 11598104.
32. McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem 2005, 280:20493-20502. 10.1074/jbc.M409985200, 15772080.
33. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174. 209533, 11602624.
34. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137. 10.1016/j.cell.2006.08.033, 16962653.
35. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 1998, 92:3410-3415.
36. Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet 1999, 8:185-193. 10.1093/hmg/8.2.185, 9931326.
37. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009, 23:1432-1440. 10.1038/leu.2009.49, 19295548.
38. Gingras AC, Raught B, Sonenberg N. mTOR signaling to translation. Curr Top Microbiol Immunol 2004, 279:169-197.
39. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006, 124:471-484. 10.1016/j.cell.2006.01.016, 16469695.
40. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008, 111:379-382. 10.1182/blood-2007-03-080796, 17878402.
41. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
42. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010, 1:89-103. 2911128, 20671809.
43. Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol 2002, 22:6247-6260. 10.1128/MCB.22.17.6247-6260.2002, 134003, 12167717.
44. Horike N, Takemori H, Katoh Y, Doi J, Min L, Asano T, et al. Adipose-specific expression, phosphorylation of Ser794 in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2. J Biol Chem 2003, 278:18440-18447. 10.1074/jbc.M211770200, 12624099.
45. Tzatsos A, Tsichlis PN. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 2007, 282:18069-18082. 10.1074/jbc.M610101200, 17459875.
46. Qiao LY, Zhande R, Jetton TL, Zhou G, Sun XJ. In vivo phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in insulin-resistant rodents. J Biol Chem 2002, 277:26530-26539. 10.1074/jbc.M201494200, 12006586.
47. Ning J, Clemmons DR. AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol 2010, 24:1218-1229. 10.1210/me.2009-0474, 20363874.
48. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004, 279:1304-1309. 10.1074/jbc.M310389200, 14557259.
49. Bertrand L, Ginion A, Beauloye C, Hebert AD, Guigas B, Hue L, et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 2006, 291:H239-250. 10.1152/ajpheart.01269.2005, 16489105.
50. Berggreen C, Gormand A, Omar B, Degerman E, Goransson O. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. Am J Physiol Endocrinol Metab 2009, 296:E635-646. 10.1152/ajpendo.90596.2008, 19158325.
51. Horman S, Vertommen D, Heath R, Neumann D, Mouton V, Woods A, et al. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J Biol Chem 2006, 281:5335-5340. 10.1074/jbc.M506850200, 16340011.
52. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol Chem 2003, 278:39422-39427. 10.1074/jbc.M305371200, 12890675.
53. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000, 14:783-794. 10.1210/me.14.6.783, 10847581.
54. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115:577-590. 10.1016/S0092-8674(03)00929-2, 14651849.
55. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008, 30:214-226. 10.1016/j.molcel.2008.03.003, 2674027, 18439900.
56. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 2006, 11:583-589. 10.1016/j.devcel.2006.08.013, 16962829.
57. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 2006, 11:859-871. 10.1016/j.devcel.2006.10.007, 17141160.
58. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008, 181:8633-8641. 2756051, 19050283.
59. Vorwerk P, Mohnike K, Wex H, Rohl FW, Zimmermann M, Blum WF, et al. Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005, 90:3022-3027. 10.1210/jc.2004-0461, 15687344.
60. Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology of HOX genes and their role in cancer. J Pathol 2005, 205:154-171. 10.1002/path.1710, 15643670.
61. Whelan JT, Ludwig DL, Bertrand FE. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia. Leukemia 2008, 22:1161-1169. 10.1038/leu.2008.57, 18337761.
62. Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006, 20:1254-1260. 10.1038/sj.leu.2404217, 16642049.
63. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681. 10.1124/pr.58.3.10, 16968952.